Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
vTv Therapeutics Inc. (VTVT)
USD32.20
+0.32 (+1.00%)
US NASDAQ Healthcare Biotechnology
Address
3980 Premier Drive 27265
High Point, NC, US
High Point, NC, US
CEO
Paul J. Sekhri
Website
vtvtherapeutics.com
IPO
2015-07-30
CIK 1641489 ISIN US9183852048
Description
vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis. Beyond these, vTv Therapeutics' broader clinical portfolio includes: TTP273, an oral small-molecule GLP-1 receptor agonist addressing postprandial glucose excursions in cystic fibrosis-related diabetes. HPP3033, which employs a non-electrophilic strategy to activate the Nrf2 pathway for chronic conditions linked to oxidative stress. Azeliragon, a RAGE antagonist being evaluated for inflammatory lung disorders, notably severe COVID-19, alongside pancreatic and breast cancers. HPP971, an Nrf2 activator aimed at renal diseases, developed in collaboration with pharmaceutical partners. Furthermore, vTv holds a licensing agreement with Reneo Pharmaceuticals, Inc. for the development and commercialization of its peroxisome proliferation-activated receptor delta agonist program, which features the compound HPP593. The company has also established various other licensing and research collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Established in 2015, vTv Therapeutics is headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD32.20
+0.32 (+1.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
52.9K
Beta
0.27
Float Shares
1.41M
Free Float %
54.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.42% | +3.58% | -13.45% | -5.20% | +2.69% | -19.70% | +54.38% | -6.55% | -64.64% | -84.71% | -92.63% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (14 ratings, all time)
Buy
Price Targets & DCF
Current price
32.20
Low
47.00
+46.0%
Consensus
51.33
+59.4%
Median
49.00
+52.2%
High
58.00
+80.1%
DCF (Unlevered)
10.43
-67.6%
DCF (Levered)
10.56
-67.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 6 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 3 |
51.33
+59.4%
|
| All Time | 3 |
51.33
+59.4%
|
Quality scores
Altman Z-Score
-3.32
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%+0.0% Q1'26: +314.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%— Q1'26: +24.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%— Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+46.0% Q1'26: +122.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 6 Rev. Ana. 4 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
519.0K
est: 344.8K (+50.5%)
|
634.0K
est: 607.5K (+4.4%)
|
291.0K
est: 129.0K (+125.6%)
|
12.43M
est: 9.98M (+24.6%)
|
2.76M
est: 4.03M (-31.5%)
|
6.41M
est: 1.66M (+287.0%)
|
4.01M
est: 4.33M (-7.5%)
|
2.02M
est: 2.01M (+0.6%)
|
1.02M
est: 1.00M (+1.7%)
|
—
|
13.33M
13.33M – 13.33M
|
800.0K
800.0K – 800.0K
-94.0% YoY
|
5.80M
5.80M – 5.80M
+625.0% YoY
|
8.23M
8.23M – 8.23M
+42.0% YoY
|
57.94M
57.94M – 57.94M
+603.7% YoY
|
| EBITDA |
-38.87M
est: -206.9K (-18,691.9%)
|
-54.69M
est: -17.35M (-215.1%)
|
-50.56M
est: -12.21M (-314.0%)
|
-20.14M
est: -3.87M (-420.8%)
|
-19.97M
est: -2.42M (-725.3%)
|
-12.02M
est: -994.5K (-1,108.2%)
|
-17.52M
est: -2.60M (-573.9%)
|
-24.77M
est: -5.78M (-328.4%)
|
-22.52M
est: -200.0K (-11,158.1%)
|
-32.79M
|
-2.67M
-2.67M – -2.67M
|
-160.0K
-160.0K – -160.0K
+94.0% YoY
|
-1.16M
-1.16M – -1.16M
-625.0% YoY
|
-1.65M
-1.65M – -1.65M
-42.0% YoY
|
-11.59M
-11.59M – -11.59M
-603.7% YoY
|
| EBIT |
-39.33M
est: -206.9K (-18,914.7%)
|
-54.96M
est: -60.43M (+9.1%)
|
-50.76M
est: -51.24M (+0.9%)
|
-20.36M
est: -19.16M (-6.2%)
|
-20.01M
est: -2.42M (-726.9%)
|
-12.11M
est: -994.5K (-1,117.7%)
|
-17.60M
est: -2.60M (-577.3%)
|
-24.86M
est: -5.91M (-320.3%)
|
-22.61M
est: -200.0K (-11,202.6%)
|
-32.81M
|
-2.67M
-2.67M – -2.67M
|
-160.0K
-160.0K – -160.0K
+94.0% YoY
|
-1.16M
-1.16M – -1.16M
-625.0% YoY
|
-1.65M
-1.65M – -1.65M
-42.0% YoY
|
-11.59M
-11.59M – -11.59M
-603.7% YoY
|
| Net Income |
-27.50M
est: -470.92M (+94.2%)
|
-16.35M
est: -17.88M (+8.5%)
|
-16.14M
est: -16.31M (+1.0%)
|
-7.91M
est: -7.40M (-6.9%)
|
-21.94M
est: -103.88M (+78.9%)
|
-8.50M
est: -60.02M (+85.8%)
|
-12.99M
est: -39.24M (+66.9%)
|
-19.16M
est: -6.38M (-200.6%)
|
-18.46M
est: -30.75M (+40.0%)
|
-26.97M
est: -36.85M (+26.8%)
|
-28.44M
-38.96M – -8.38M
+22.8% YoY
|
-35.00M
-47.02M – -22.97M
-23.1% YoY
|
-40.52M
-59.47M – -21.56M
-15.8% YoY
|
-34.91M
-34.91M – -34.91M
+13.8% YoY
|
-12.53M
-12.53M – -12.53M
+64.1% YoY
|
| SGA |
9.08M
est: 1.70M (+433.4%)
|
9.91M
est: 3.00M (+230.3%)
|
11.33M
est: 636.8K (+1,679.7%)
|
9.22M
est: 8.83M (+4.4%)
|
8.54M
est: 19.91M (-57.1%)
|
7.25M
est: 8.18M (-11.4%)
|
12.34M
est: 21.38M (-42.3%)
|
12.20M
est: 9.90M (+23.2%)
|
13.65M
est: 4.91M (+178.0%)
|
14.95M
|
65.47M
65.47M – 65.47M
|
3.93M
3.93M – 3.93M
-94.0% YoY
|
28.48M
28.48M – 28.48M
+625.0% YoY
|
40.43M
40.43M – 40.43M
+42.0% YoY
|
284.49M
284.49M – 284.49M
+603.7% YoY
|
| EPS |
-132.90
est: -81.60 (-62.9%)
|
-68.52
est: -72.27 (+5.2%)
|
-66.62
est: -65.60 (-1.6%)
|
-25.42
est: -34.00 (+25.2%)
|
-28.97
est: -18.00 (-60.9%)
|
-7.21
est: -10.40 (+30.7%)
|
-8.29
est: -6.80 (-21.9%)
|
-9.98
est: -10.80 (+7.6%)
|
-3.20
est: -3.65 (+12.3%)
|
-3.20
est: -4.15 (+22.8%)
|
-2.57
-4.62 – -0.99
+38.1% YoY
|
-3.72
-5.58 – -2.73
-44.9% YoY
|
-3.94
-7.06 – -2.56
-5.9% YoY
|
-4.14
-4.14 – -4.14
-5.2% YoY
|
-1.49
-1.49 – -1.49
+64.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-25.49M
OE per share TTM
-3.42
Owner's Yield
-9.42%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
22.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
13
Total invested
5.50M
Insider transactions (90d)
0
Beneficial owners (>5%)
23
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | The ROP Revocable Trust dated 1/9/2018 | 61.51M | 85.30% | — | 61.51M | — | 61.51M | OO | — | 2020-02-25 | ↗ |
| 2 | MacAndrews & Forbes Incorporated | 60.81M | 84.40% | — | 60.81M | — | 60.81M | CO | — | 2020-02-25 | ↗ |
| 3 | MFV Holdings One LLC | 40.02M | 59.10% | — | 40.02M | — | 40.02M | OO | — | 2020-02-25 | ↗ |
| 4 | M&F TTP Holdings LLC | 22.38M | 33.00% | — | 22.38M | — | 22.38M | OO | — | 2020-02-25 | ↗ |
| 5 | M&F TTP Holdings Two LLC | 22.38M | 33.00% | — | 22.38M | — | 22.38M | OO | — | 2020-02-25 | ↗ |
| 6 | MacAndrews & Forbes Group LLC | 20.79M | 28.80% | — | 20.79M | — | 20.79M | OO | — | 2020-02-25 | ↗ |
| 7 | MacAndrews & Forbes LLC | 20.79M | 28.80% | — | 20.79M | — | 20.79M | OO | — | 2020-02-25 | ↗ |
| 8 | G42 Investments AI Holding RSC Ltd | 10.39M | 13.40% | — | 10.39M | — | 10.00 | OO | United Arab Emirates | 2022-06-10 | ↗ |
| 9 | Tahnoon Bin Zayed S. Al-Nahyan | 10.39M | 13.40% | — | 10.39M | — | 10.00 | HC, IN | United Arab Emirates | 2022-06-10 | ↗ |
| 10 | August J. Troendle | 5.40M | 5.16% | — | 5.40M | — | 5.40M | OO | Delaware | 2022-08-23 | ↗ |
| 11 | Medpace Investors, LLC | 5.40M | 5.16% | 1.24M | 4.15M | 1.24M | 4.15M | OO | Delaware | 2022-08-23 | ↗ |
| 12 | Franklin Resources, Inc. | 952.9K | 12.20% | 4.00 | 4.00 | 4.00 | 4.00 | EP, IN | Delaware | 2015-09-10 | ↗ |
| 13 | Samsara BioCapital GP, LLC | 265.6K | 10.40% | — | 265.6K | — | 10.00 | OO | Delaware | 2024-03-05 | ↗ |
| 14 | Samsara BioCapital, L.P. | 265.6K | 10.40% | — | 265.6K | — | 10.00 | PN | Delaware | 2024-03-05 | ↗ |
| 15 | Srinivas Akkaraju | 265.6K | 10.40% | — | 265.6K | — | 10.00 | IN | United States | 2024-03-05 | ↗ |
| 16 | Piper Jaffray & Co. | 181.9K | 1.90% | 181.9K | — | 181.9K | — | BD | Delaware | 2016-12-28 | ↗ |
| 17 | Piper Jaffray Companies | 181.9K | 1.90% | — | 181.9K | — | 181.9K | HC | Delaware | 2016-12-28 | ↗ |
| 18 | Abigail P. Johnson | 178.2K | 7.32% | — | — | 178.2K | — | IN | Delaware | 2024-11-12 | ↗ |
| 19 | FMR LLC | 178.2K | 7.32% | 178.2K | — | 178.2K | — | HC | Delaware | 2024-11-12 | ↗ |
| 20 | Baker Bros. Advisors (GP) LLC | 122.7K | 4.99% | 122.7K | — | 122.7K | — | HC, OO | Delaware | 2024-03-05 | ↗ |
| 21 | Baker Bros. Advisors LP | 122.7K | 4.99% | 122.7K | — | 122.7K | — | IA, PN | Delaware | 2024-03-05 | ↗ |
| 22 | Felix J. Baker | 122.7K | 4.99% | 122.7K | — | 122.7K | — | HC, IN | United States | 2024-03-05 | ↗ |
| 23 | Julian C. Baker | 122.7K | 4.99% | 122.7K | — | 122.7K | — | HC, IN | United States | 2024-03-05 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
13
-13 vs prev Q
New positions
5
Closed positions
18
Increased
7
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 231.0K +231.0K (+100.0%) | 9.24B +9.2B (+100.0%) | 2.87% +2.867 pp | 2.28% +2.282 pp | USD39.99 +0.0% | 1 qtrs NEW |
| 2 | SAMSARA BIOCAPITAL, LLC | 298.5K -76.0K (-20.3%) | 11.94M +3.2M (+36.5%) | 3.71% -1.980 pp | 1.23% +0.090 pp | USD22.88 +74.8% | 9 qtrs — |
| 3 | FMR LLC | 268.9K +76.0K (+39.4%) | 10.75M +6.3M (+139.6%) | 3.34% +0.409 pp | 0.00% +0.000 pp | USD21.57 +85.4% | 8 qtrs — |
| 4 | SIREN, L.L.C. | 163.0K +— (+0.0%) | 6.52M +2.7M (+71.3%) | 2.02% -0.451 pp | 0.19% +0.046 pp | USD23.35 +71.3% | 2 qtrs — |
| 5 | BAKER BROS. ADVISORS LP | 148.3K +— (+0.0%) | 5.93M +2.5M (+71.3%) | 1.84% -0.411 pp | 0.03% +0.010 pp | USD24.56 +62.8% | 8 qtrs — |
| 6 | VANGUARD GROUP INC | 83.4K +36.4K (+77.5%) | 3.34M +2.2M (+205.1%) | 1.04% +0.322 pp | 0.00% +0.000 pp | USD25.14 +59.1% | 9 qtrs — |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 28.2K +12.9K (+84.3%) | 1.13M +771.6K (+216.8%) | 0.35% +0.118 pp | 0.00% +0.000 pp | USD26.65 +50.1% | 6 qtrs — |
| 8 | 683 CAPITAL MANAGEMENT, LLC | 18.3K +18.3K (+100.0%) | 730.5K +730.5K (+100.0%) | 0.23% +0.227 pp | 0.03% +0.032 pp | USD39.99 +0.0% | 1 qtrs NEW |
| 9 | NORTHERN TRUST CORP | 16.1K +2.0K (+14.1%) | 641.9K +313.3K (+95.4%) | 0.20% -0.014 pp | 0.00% +0.000 pp | USD20.12 +98.8% | 4 qtrs — |
| 10 | BLACKROCK, INC. | 10.6K +5.7K (+114.9%) | 424.1K +308.9K (+268.1%) | 0.13% +0.057 pp | 0.00% +0.000 pp | USD27.81 +43.8% | 6 qtrs — |
| 11 | PATHSTONE HOLDINGS, LLC | 6.1K +6.1K (+100.0%) | 242.9K +242.9K (+100.0%) | 0.08% +0.075 pp | 0.00% +0.001 pp | USD39.99 +0.0% | 1 qtrs NEW |
| 12 | GOLDMAN SACHS GROUP INC | 5.5K +5.5K (+100.0%) | 221.2K +221.2K (+100.0%) | 0.07% +0.069 pp | 0.00% +0.000 pp | USD39.99 +0.0% | 1 qtrs NEW |
| 13 | UBS GROUP AG | 1.7K -1.3K (-43.8%) | 66.7K -2.6K (-3.8%) | 0.02% -0.024 pp | 0.00% +0.000 pp | USD14.92 +168.0% | 8 qtrs — |
| 14 | TOWER RESEARCH CAPITAL LLC (TRC) | 1.3K +1.3K (+100.0%) | 50.7K +50.7K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.001 pp | USD39.99 +0.0% | 1 qtrs NEW |
| 15 | ADVISOR GROUP HOLDINGS, INC. | 1.1K -500.0 (-30.9%) | 44.8K +7.6K (+20.5%) | 0.01% -0.011 pp | 0.00% +0.000 pp | USD22.94 +74.3% | 9 qtrs — |
| 16 | MORGAN STANLEY | 977.00 +231.0 (+31.0%) | 39.1K +21.7K (+124.3%) | 0.01% +0.001 pp | 0.00% +0.000 pp | USD18.71 +113.7% | 9 qtrs — |
| 17 | FARTHER FINANCE ADVISORS, LLC | 279.00 +279.0 (+100.0%) | 11.2K +11.2K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD39.99 +0.0% | 1 qtrs NEW |
| 18 | CITIGROUP INC | 244.00 +243.0 (+24,300.0%) | 9.8K +9.7K (+42,326.1%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD39.92 +0.2% | 2 qtrs — |
| 19 | BESSEMER GROUP INC | 112.00 +112.0 (+100.0%) | 4.0K +4.0K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD39.98 +0.0% | 1 qtrs NEW |
| 20 | ACTIVEST WEALTH MANAGEMENT | 50.00 +— (+0.0%) | 2.0K +832.0 (+71.2%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD17.58 +127.5% | 7 qtrs — |
| 21 | CORECAP ADVISORS, LLC | 45.00 +— (+0.0%) | 1.8K +749.0 (+71.3%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD17.31 +131.0% | 4 qtrs — |
| 22 | PARALLEL ADVISORS, LLC | 38.00 +— (+0.0%) | 1.5K +633.0 (+71.4%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD11.50 +247.7% | 9 qtrs — |
| 23 | SUNBELT SECURITIES, INC. | 15.00 +— (+0.0%) | 600.00 +250.0 (+71.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.47 +8,408.5% | 10 qtrs — |
| 24 | BNP PARIBAS ARBITRAGE, SNC | 9.00 +— (+0.0%) | 360.00 +150.0 (+71.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD25.11 +59.3% | 8 qtrs — |
| 25 | BANK OF AMERICA CORP /DE/ | 4.00 +3.0 (+300.0%) | 160.00 +137.0 (+595.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD35.25 +13.4% | 9 qtrs — |
| 26 | SBI SECURITIES CO., LTD. | 2.00 +— (+0.0%) | 80.00 +33.0 (+70.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD17.00 +135.2% | 4 qtrs — |
| 27 | STRENGTHENING FAMILIES & COMMUNITIES, LLC | — -173.0 (-100.0%) | — -4.0K (-100.0%) | 0.00% -0.003 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 28 | MILLENNIUM MANAGEMENT LLC | — -12.9K (-100.0%) | — -300.9K (-100.0%) | 0.00% -0.196 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 29 | CONNECTIVE CAPITAL MANAGEMENT, LLC | — -9.7K (-100.0%) | — -226.8K (-100.0%) | 0.00% -0.147 pp | 0.00% -0.208 pp | USD— | 4 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 14 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.50% | 110.2K | 0.20% |
| 2 | iShares Micro-Cap ETF IWC | 0.02% | 242.3K | 0.60% |
| 3 | Vanguard Extended Market ETF VXF | 0.00% | 1.02M | 0.05% |
| 4 | Avantis U.S. Small Cap Equity ETF AVSC | 0.00% | 11.8K | 0.25% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 1.1K | 0.17% |
| 6 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 5.3K | 0.03% |
| 7 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 14.4K | 0.17% |
| 8 | Vanguard Total Stock Market ETF VTI | 0.00% | 2.47M | 0.03% |
| 9 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 5.4K | 0.22% |
| 10 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 2.9K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
185.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+184,969
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-17 | Tung Michael Stephen | Officer | A-Award | A | Employee stock option (right to buy) | 44,969 | 36.92 | 1.66M | 89,969 | D | ↗ |
| 2026-02-17 | SEKHRI PAUL J | Director / Officer | A-Award | A | Class A Common Stock | 140,000 | 36.92 | 5.17M | 392,212 | D | ↗ |
| 2025-09-22 | AKKARAJU SRINIVAS | Director | A-Award | A | Warrant (Right to Buy) | 983,214 | 22.71 | 22.33M | 983,214 | I | ↗ |
| 2025-09-03 | BAKER BROS. ADVISORS LP | Director | A-Award | A | Prefunded Warrants | 2,353,913 | 0.01 | 23.5K | 5,176,974 | I | ↗ |
| 2025-09-03 | AKKARAJU SRINIVAS | Director | A-Award | A | Pre-Funded Warrants (Right to Buy) | 655,523 | 0.01 | 6.6K | 1,548,101 | I | ↗ |
| 2025-06-10 | SPIEGELMAN DANIEL K | Director | A-Award | A | Director stock option (right to buy) | 4,000 | 16.59 | 66.4K | 10,000 | D | ↗ |
| 2025-06-10 | Phillips Anne M. | Director | A-Award | A | Director stock option (right to buy) | 4,000 | 16.59 | 66.4K | 10,860 | D | ↗ |
| 2025-06-10 | BAKER BROS. ADVISORS LP | Director | A-Award | A | Non- Qualified Stock Option (right to buy) | 4,000 | 16.59 | 66.4K | 4,000 | I | ↗ |
| 2025-06-10 | Al-Marzooqi Fahed | Director | A-Award | A | Director stock option (right to buy) | 4,000 | 16.59 | 66.4K | 13,555 | D | ↗ |
| 2025-06-10 | AKKARAJU SRINIVAS | Director | A-Award | A | Director stock option (right to buy) | 4,000 | 16.59 | 66.4K | 10,983 | D | ↗ |
| 2025-05-19 | Tung Michael Stephen | Officer | A-Award | A | Employee stock option (right to buy) | 45,000 | 21.25 | 956.3K | 45,000 | D | ↗ |
| 2025-04-11 | Brown Barry K. | Officer | — | — | Employee stock option (right to buy) | 250 | 368.80 | 92.2K | 0 | D | ↗ |
| 2025-03-01 | SEKHRI PAUL J | Director / Officer | A-Award | A | Employee stock option (right to buy) | 108,000 | 19.66 | 2.12M | 252,212 | D | ↗ |
| 2024-11-18 | SEKHRI PAUL J | Director / Officer | P-Purchase | A | Class A Common Stock | 1,844 | 16.96 | 31.3K | 5,000 | D | ↗ |
| 2024-11-15 | SEKHRI PAUL J | Director / Officer | P-Purchase | A | Class A Common Stock | 1,778 | 16.88 | 30.0K | 3,156 | D | ↗ |
| 2024-06-25 | SPIEGELMAN DANIEL K | Director | A-Award | A | Director stock option (right to buy) | 6,000 | 17.22 | 103.3K | 6,000 | — | ↗ |
| 2024-06-25 | Phillips Anne M. | Director | A-Award | A | Director stock option (right to buy) | 860 | 17.22 | 14.8K | 6,860 | — | ↗ |
| 2024-06-25 | BAKER BROS. ADVISORS LP | Director | A-Award | A | Non- Qualified Stock Option (right to buy) | 983 | 17.22 | 16.9K | 983 | — | ↗ |
| 2024-06-25 | Al-Marzooqi Fahed | Director | A-Award | A | Director stock option (right to buy) | 3,000 | 17.22 | 51.7K | 9,555 | — | ↗ |
| 2024-06-25 | AKKARAJU SRINIVAS | Director | A-Award | A | Director stock option (right to buy) | 2,250 | 17.22 | 38.7K | 6,000 | D | ↗ |
| 2024-06-11 | SPIEGELMAN DANIEL K | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-13 | Phillips Anne M. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-05 | Samsara BioCapital GP, LLC | 10% Owner | J-Other | D | Class A Common Stock | 58,836 | 0.01 | 588.36 | 206,784 | I | ↗ |
| 2024-03-05 | BAKER BROS. ADVISORS LP | Director | D-Return | D | Common Stock | 4,776 | 0.00 | — | 8,060 | — | ↗ |
| 2024-03-05 | AKKARAJU SRINIVAS | Director / 10% Owner | D-Return | D | Class A Common Stock | 58,836 | 0.01 | 588.36 | 206,784 | I | ↗ |
| 2024-02-27 | Tuch Steven L. | Officer | A-Award | A | Employee stock option (right to buy) | 62,159 | 11.81 | 734.1K | 74,659 | — | ↗ |
| 2024-02-27 | Samsara BioCapital GP, LLC | 10% Owner | — | I | Pre-Funded Warrants (Right to Buy) | 833,693 | 0.01 | 8.3K | 0 | — | ↗ |
| 2024-02-27 | SEKHRI PAUL J | Director / Officer | A-Award | A | Employee stock option (right to buy) | 89,212 | 11.81 | 1.05M | 144,212 | — | ↗ |
| 2024-02-27 | Cheong Raymond | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-27 | BAKER BROS. ADVISORS LP | Director | — | I | Common Stock | 0 | 0.00 | — | 12,836 | — | ↗ |
| 2024-02-27 | Al-Marzooqi Fahed | Director | A-Award | A | Director stock option (right to buy) | 4,055 | 11.81 | 47.9K | 6,555 | — | ↗ |
| 2024-02-27 | AKKARAJU SRINIVAS | Director / 10% Owner | A-Award | A | Pre- Funded Warrants (Right to Buy) | 833,693 | 0.01 | 8.3K | 833,693 | — | ↗ |
| 2024-02-23 | AKKARAJU SRINIVAS | Director / 10% Owner | — | I | Class A Common Stock | 0 | 0.00 | — | 40,888 | — | ↗ |
| 2023-06-19 | Weiner Howard L. | Director | A-Award | A | Director stock option (right to buy) | 75,000 | 0.80 | 60.0K | 75,000 | — | ↗ |
| 2023-06-19 | KOZLOV HERSH | Director | A-Award | A | Director stock option (right to buy) | 75,000 | 0.80 | 60.0K | 75,000 | — | ↗ |
| 2023-06-19 | Harris Keith R. | Director | A-Award | A | Director stock option (right to buy) | 75,000 | 0.80 | 60.0K | 75,000 | — | ↗ |
| 2023-06-19 | Harjivan Chandresh | Director | A-Award | A | Director stock option (right to buy) | 75,000 | 0.80 | 60.0K | 75,000 | — | ↗ |
| 2023-06-19 | FRY JOHN A | Director | A-Award | A | Director stock option (right to buy) | 75,000 | 0.80 | 60.0K | 75,000 | — | ↗ |
| 2023-06-19 | Al-Marzooqi Fahed | Director | A-Award | A | Director stock option (right to buy) | 75,000 | 0.80 | 60.0K | 75,000 | — | ↗ |
| 2022-12-12 | Tuch Steven L. | Officer | A-Award | A | Director stock option (right to buy) | 500,000 | 0.00 | — | 500,000 | — | ↗ |
| 2022-12-08 | Tuch Steven L. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-11-29 | FRY JOHN A | Director | P-Purchase | A | Class A common stock | 40,461 | 0.83 | 33.8K | 61,000 | — | ↗ |
| 2022-11-28 | FRY JOHN A | Director | P-Purchase | A | Class A common stock | 20,539 | 0.83 | 17.0K | 20,539 | — | ↗ |
| 2022-08-17 | Isaacsohn Jonathan | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-08-09 | Isaacsohn Jonathan | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-08-01 | SEKHRI PAUL J | Officer | — | D | Employee stock option (right to buy) | 2,200,000 | 0.79 | 1.74M | 0 | — | ↗ |
| 2022-07-13 | Harris Keith R. | Director | A-Award | A | Director stock option (right to buy) | 25,000 | 0.69 | 17.3K | 25,000 | — | ↗ |
| 2022-07-13 | Al-Marzooqi Fahed | Director | A-Award | A | Director stock option (right to buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-07-11 | Harris Keith R. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-07-01 | Weiner Howard L. | Director | A-Award | A | Director stock option (right to buy) | 105,128 | 0.72 | 75.7K | 105,128 | — | ↗ |
| 2022-07-01 | KOZLOV HERSH | Director | A-Award | A | Director stock option (right to buy) | 105,128 | 0.00 | — | 105,128 | — | ↗ |
| 2022-07-01 | Harjivan Chandresh | Director | A-Award | A | Director stock option (right to buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-07-01 | FRY JOHN A | Director | A-Award | A | Director stock option (right to buy) | 137,077 | 0.00 | — | 137,077 | — | ↗ |
| 2022-06-01 | Harjivan Chandresh | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-05-31 | G42 Investments AI Holdings RSC Ltd. | Director | — | D | Class A Common Stock ("Common Stock") | 0 | 0.00 | — | 10,386,274 | — | ↗ |
| 2022-05-31 | Al-Nahyan Tahnoon Bin Zayed S. | Director | — | I | Class A Common Stock ("Common Stock") | 0 | 0.00 | — | 10,386,274 | — | ↗ |
| 2022-03-29 | Brown Barry K. | Officer | — | D | Employee stock option (right to buy) | 200,000 | 0.71 | 142.0K | 0 | — | ↗ |
| 2022-03-03 | Nelson Rich S. | Officer | A-Award | A | Employee stock option (right to buy) | 500,000 | 0.00 | — | 500,000 | — | ↗ |
| 2021-12-20 | PERELMAN RONALD O | Director | S-Sale | D | Class A Common Stock | 87,000 | 1.15 | 100.1K | 36,519,212 | — | ↗ |
| 2021-10-19 | Prasad Deepa | Officer | A-Award | A | Employee stock option (right to buy) | 2,498,635 | 0.00 | — | 2,498,635 | — | ↗ |
| 2021-05-03 | Weiner Howard L. | Director | A-Award | A | Director stock option (right to buy) | 15,000 | 2.54 | 38.1K | 71,250 | — | ↗ |
| 2021-05-03 | Spiegel Noel Joseph | Director | A-Award | A | Director stock option (right to buy) | 15,000 | 2.54 | 38.1K | 115,000 | — | ↗ |
| 2021-05-03 | KOZLOV HERSH | Director | A-Award | A | Director stock option (right to buy) | 15,000 | 0.00 | — | 41,250 | — | ↗ |
| 2021-05-03 | FRY JOHN A | Director | A-Award | A | Director stock option (right to buy) | 15,000 | 0.00 | — | 92,500 | — | ↗ |
| 2021-02-26 | Nelson Rich S. | Director | P-Purchase | A | Class A common stock | 10,000 | 2.86 | 28.6K | 10,000 | — | ↗ |
| 2021-02-26 | KOZLOV HERSH | Director | P-Purchase | A | Class A common stock | 10,000 | 2.74 | 27.4K | 25,000 | — | ↗ |
| 2020-12-30 | Abrams Robin Elizabeth | Director | — | D | Employee stock option (right to buy) | 30,000 | 6.85 | 205.5K | 0 | — | ↗ |
| 2020-12-17 | PERELMAN RONALD O | Director | P-Purchase | A | Class A Common Stock | 625,000 | 1.60 | 1.00M | 36,606,212 | — | ↗ |
| 2020-12-10 | PERELMAN RONALD O | Director | P-Purchase | A | Class A Common Stock | 625,000 | 1.60 | 1.00M | 35,981,212 | — | ↗ |
| 2020-12-07 | Holcombe Stephen L. | Officer | A-Award | A | Employee stock option (right to buy) | 400,000 | 2.07 | 828.0K | 945,579 | — | ↗ |
| 2020-12-07 | HOWARD RUDY | Director | A-Award | A | Employee stock option (right to buy) | 250,000 | 0.00 | — | 594,914 | — | ↗ |
| 2020-11-24 | PERELMAN RONALD O | Director | P-Purchase | A | Class A Common Stock | 625,000 | 1.60 | 1.00M | 35,356,212 | — | ↗ |
| 2020-11-16 | Nelson Rich S. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-08-31 | Taibi Edward P. | Director | — | D | Class A common stock | 0 | 0.00 | — | 1,332 | — | ↗ |
| 2020-06-11 | Weiner Howard L. | Director | A-Award | A | Director stock option (right to buy) | 15,000 | 2.65 | 39.8K | 56,250 | — | ↗ |
| 2020-06-11 | Spiegel Noel Joseph | Director | A-Award | A | Director stock option (right to buy) | 15,000 | 2.65 | 39.8K | 100,000 | — | ↗ |
| 2020-06-11 | KOZLOV HERSH | Director | A-Award | A | Director stock option (right to buy) | 26,250 | 2.65 | 69.6K | 26,250 | — | ↗ |
| 2020-06-11 | KINDLER JEFFREY B | Director | A-Award | A | Director stock option (right to buy) | 15,000 | 2.65 | 39.8K | 78,121 | — | ↗ |
| 2020-06-11 | FRY JOHN A | Director | A-Award | A | Director stock option (right to buy) | 15,000 | 2.65 | 39.8K | 77,500 | — | ↗ |
| 2020-05-15 | KOZLOV HERSH | Director | P-Purchase | A | Class A common stock | 10,000 | 3.00 | 30.0K | 15,000 | — | ↗ |
| 2020-05-12 | PERELMAN RONALD O | 10% Owner | O-OutOfTheMoney | D | Call Option (right to buy) | 1 | 1.60 | 1.60 | 1 | — | ↗ |
| 2020-03-10 | KINDLER JEFFREY B | Director | M-Exempt | A | Class A Common Stock | 11,667 | 0.00 | — | 35,000 | — | ↗ |
| 2020-02-25 | PERELMAN RONALD O | Director | P-Purchase | A | Class A Common Stock | 1,250,000 | 1.60 | 2.00M | 34,106,212 | — | ↗ |
| 2020-01-28 | PERELMAN RONALD O | Director | P-Purchase | A | Class A Common Stock | 1,250,000 | 1.60 | 2.00M | 32,856,212 | — | ↗ |
| 2020-01-07 | PERELMAN RONALD O | Director | P-Purchase | A | Class A Common Stock | 1,250,000 | 1.60 | 2.00M | 31,606,212 | — | ↗ |
| 2019-12-23 | PERELMAN RONALD O | Director | J-Other | A | Common Stock Purchase Warrant | 1 | 1.84 | 1.84 | 1 | — | ↗ |
| 2019-12-18 | PERELMAN RONALD O | Director | O-OutOfTheMoney | D | Call Option (right to buy) | 1 | 0.01 | 0.01 | 1 | — | ↗ |
| 2019-11-29 | KINDLER JEFFREY B | Director | A-Award | A | Director stock option (right to buy) | 35,000 | 2.18 | 76.3K | 63,121 | — | ↗ |
| 2019-11-26 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 1,369,863 | 1.46 | 2.00M | 28,986,349 | — | ↗ |
| 2019-11-12 | PERELMAN RONALD O | Director | O-OutOfTheMoney | D | Call Option (right to buy) | 1 | 0.01 | 0.01 | 1 | — | ↗ |
| 2019-10-24 | PERELMAN RONALD O | Director | O-OutOfTheMoney | D | Call Option (right to buy) | 1 | 0.01 | 0.01 | 1 | — | ↗ |
| 2019-09-27 | PERELMAN RONALD O | 10% Owner | O-OutOfTheMoney | D | Call Option (right to buy) | 1 | 1.46 | 1.46 | 1 | — | ↗ |
| 2019-09-26 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 1,369,863 | 1.46 | 2.00M | 24,876,760 | — | ↗ |
| 2019-09-18 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 606,061 | 1.65 | 1.00M | 23,506,897 | — | ↗ |
| 2019-09-13 | KOZLOV HERSH | Director | P-Purchase | A | Class A common stock | 5,000 | 1.65 | 8.3K | 5,000 | — | ↗ |
| 2019-09-11 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 606,061 | 1.65 | 1.00M | 22,900,836 | — | ↗ |
| 2019-09-11 | KOZLOV HERSH | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-09-04 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 606,061 | 1.65 | 1.00M | 22,294,775 | — | ↗ |
| 2019-08-22 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 50,000 | 1.38 | 69.0K | 21,688,714 | — | ↗ |
| 2019-08-19 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 150,000 | 1.31 | 195.9K | 21,638,714 | — | ↗ |
| 2019-08-06 | PERELMAN RONALD O | 10% Owner | O-OutOfTheMoney | D | Call Option (right to buy) | 1 | 1.65 | 1.65 | 1 | — | ↗ |
| 2019-07-09 | PERELMAN RONALD O | Director | O-OutOfTheMoney | D | Call Option (right to buy) | 1 | 0.00 | — | 1 | — | ↗ |
| 2019-06-25 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 1,212,121 | 1.65 | 2.00M | 19,064,472 | — | ↗ |
| 2019-05-15 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 1,358,698 | 1.84 | 2.50M | 17,852,351 | — | ↗ |
| 2019-04-29 | Weiner Howard L. | Director | A-Award | A | Director stock option (right to buy) | 15,000 | 1.45 | 21.8K | 41,250 | — | ↗ |
| 2019-04-29 | Spiegel Noel Joseph | Director | A-Award | A | Director stock option (right to buy) | 15,000 | 1.45 | 21.8K | 85,000 | — | ↗ |
| 2019-04-29 | FRY JOHN A | Director | A-Award | A | Director stock option (right to buy) | 15,000 | 1.45 | 21.8K | 62,500 | — | ↗ |
| 2019-03-18 | PERELMAN RONALD O | Director | J-Other | A | Call Option (right to buy) | 1 | 0.01 | 0.01 | 1 | — | ↗ |
| 2019-03-10 | KINDLER JEFFREY B | Director | M-Exempt | D | Restricted Stock Units | 11,666 | 0.00 | — | 11,667 | — | ↗ |
| 2019-03-07 | Holcombe Stephen L. | Officer | A-Award | A | Employee stock option (right to buy) | 200,000 | 2.18 | 436.0K | 545,579 | — | ↗ |
| 2019-03-07 | HOWARD RUDY | Director | A-Award | A | Employee stock option (right to buy) | 125,000 | 0.00 | — | 344,914 | — | ↗ |
| 2019-02-28 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 815,217 | 1.84 | 1.50M | 16,493,653 | — | ↗ |
| 2019-02-14 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 815,217 | 1.84 | 1.50M | 15,678,436 | — | ↗ |
| 2019-01-29 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 815,217 | 1.84 | 1.50M | 14,863,219 | — | ↗ |
| 2019-01-16 | PERELMAN RONALD O | 10% Owner | O-OutOfTheMoney | D | Call Option (right to buy) | 1 | 1.84 | 1.84 | 1 | — | ↗ |
| 2018-12-27 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 815,217 | 1.84 | 1.50M | 13,232,785 | — | ↗ |
| 2018-12-11 | PERELMAN RONALD O | Director | J-Other | A | Common Stock Purchase Warrant | 1 | 2.12 | 2.12 | 1 | — | ↗ |
| 2018-11-29 | PERELMAN RONALD O | Director | O-OutOfTheMoney | D | Call Option (right to buy) | 1 | 0.00 | — | 0 | — | ↗ |
| 2018-11-06 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 1,879,699 | 1.33 | 2.50M | 10,537,868 | — | ↗ |
| 2018-09-27 | PERELMAN RONALD O | Director | O-OutOfTheMoney | D | Call Option (right to buy) | 1 | 0.00 | — | 1 | — | ↗ |
| 2018-09-06 | SAVAS PAUL G | Director | P-Purchase | A | Class A common stock | 5,000 | 1.00 | 5.0K | 91,781 | — | ↗ |
| 2018-09-06 | PERELMAN RONALD O | Director | O-OutOfTheMoney | D | Call Option (right to buy) | 1 | 0.00 | — | 1 | — | ↗ |
| 2018-08-10 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 570,777 | 4.38 | 2.50M | 4,898,771 | — | ↗ |
| 2018-07-30 | PERELMAN RONALD O | 10% Owner | J-Other | A | Call Option (right to buy) | 1 | 1.33 | 1.33 | 1 | — | ↗ |
| 2018-07-06 | PERELMAN RONALD O | 10% Owner | O-OutOfTheMoney | D | Call Option (right to buy) | 1 | 4.38 | 4.38 | 1 | — | ↗ |
| 2018-06-18 | PERELMAN RONALD O | 10% Owner | O-OutOfTheMoney | D | Call Option (right to buy) | 1 | 4.38 | 4.38 | 1 | — | ↗ |
| 2018-05-24 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 570,776 | 4.38 | 2.50M | 3,186,442 | — | ↗ |
| 2018-04-30 | Weiner Howard L. | Director | A-Award | A | Director stock option (right to buy) | 26,250 | 1.79 | 47.0K | 26,250 | — | ↗ |
| 2018-04-30 | Spiegel Noel Joseph | Director | A-Award | A | Director stock option (right to buy) | 15,000 | 1.79 | 26.9K | 70,000 | — | ↗ |
| 2018-04-30 | Parker Craig C | Director | A-Award | A | Director stock option (right to buy) | 15,000 | 1.79 | 26.9K | 70,000 | — | ↗ |
| 2018-04-30 | FRY JOHN A | Director | A-Award | A | Director stock option (right to buy) | 15,000 | 1.79 | 26.9K | 47,500 | — | ↗ |
| 2018-03-10 | KINDLER JEFFREY B | Director | M-Exempt | D | Restricted Stock Units | 11,667 | 0.00 | — | 23,333 | — | ↗ |
| 2017-12-26 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 50,000 | 4.03 | 201.7K | 2,615,666 | — | ↗ |
| 2017-12-06 | SAVAS PAUL G | Director | P-Purchase | A | Class A common stock | 10,000 | 4.55 | 45.5K | 81,781 | — | ↗ |
| 2017-12-05 | PERELMAN RONALD O | Director | J-Other | A | Common Stock Purchase Warrant | 1 | 5.04 | 5.04 | 1 | — | ↗ |
| 2017-08-22 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 20,000 | 4.57 | 91.3K | 2,565,666 | — | ↗ |
| 2017-08-16 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 10,000 | 4.97 | 49.7K | 2,545,666 | — | ↗ |
| 2017-08-14 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 15,000 | 4.88 | 73.2K | 2,535,666 | — | ↗ |
| 2017-08-10 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 60,000 | 3.98 | 239.0K | 2,460,666 | — | ↗ |
| 2017-07-31 | Weiner Howard L. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-05-12 | SAVAS PAUL G | Director | P-Purchase | A | Class A common stock | 1,900 | 5.17 | 9.8K | 71,781 | — | ↗ |
| 2017-05-01 | Spiegel Noel Joseph | Director | A-Award | A | Director stock option (right to buy) | 15,000 | 5.31 | 79.7K | 55,000 | — | ↗ |
| 2017-05-01 | Parker Craig C | Director | A-Award | A | Director stock option (right to buy) | 15,000 | 5.31 | 79.7K | 55,000 | — | ↗ |
| 2017-05-01 | FRY JOHN A | Director | A-Award | A | Director stock option (right to buy) | 15,000 | 5.31 | 79.7K | 32,500 | — | ↗ |
| 2017-03-30 | SAVAS PAUL G | Director | P-Purchase | A | Class A common stock | 2,346 | 6.54 | 15.3K | 68,781 | — | ↗ |
| 2017-03-10 | KINDLER JEFFREY B | Director | A-Award | A | Restricted Stock Unit | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2017-03-10 | Holcombe Stephen L. | Director | A-Award | A | Employee stock option (right to buy) | 165,110 | 0.00 | — | 345,579 | — | ↗ |
| 2017-03-10 | HOWARD RUDY | Director | A-Award | A | Employee stock option (right to buy) | 105,070 | 0.00 | — | 219,914 | — | ↗ |
| 2017-03-10 | ALTSTIEL LARRY DOUGLAS | Officer | A-Award | A | Employee stock option (right to buy) | 128,085 | 5.81 | 744.2K | 268,085 | — | ↗ |
| 2016-05-27 | SAVAS PAUL G | Director | P-Purchase | A | Class A common stock | 6,000 | 5.67 | 34.0K | 58,781 | — | ↗ |
| 2016-05-20 | SAVAS PAUL G | Director | P-Purchase | A | Class A common stock | 200 | 5.50 | 1.1K | 52,781 | — | ↗ |
| 2016-05-12 | Spiegel Noel Joseph | Director | A-Award | A | Director stock option (right to buy) | 15,000 | 0.00 | — | 40,000 | — | ↗ |
| 2016-05-12 | Parker Craig C | Director | A-Award | A | Director stock option (right to buy) | 15,000 | 0.00 | — | 40,000 | — | ↗ |
| 2016-05-12 | FRY JOHN A | Director | A-Award | A | Director stock option (right to buy) | 17,500 | 0.00 | — | 17,500 | — | ↗ |
| 2016-04-08 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 10,000 | 4.99 | 49.9K | 2,400,666 | — | ↗ |
| 2016-04-01 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 100,000 | 5.20 | 520.0K | 2,390,666 | — | ↗ |
| 2016-03-28 | SAVAS PAUL G | Director | P-Purchase | A | Class A common stock | 5,000 | 5.39 | 27.0K | 51,522 | — | ↗ |
| 2016-03-24 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 10,000 | 5.64 | 56.4K | 1,990,666 | — | ↗ |
| 2016-03-17 | PERELMAN RONALD O | Director | J-Other | A | Nonvoting Common Units and Class B common stock | 25,035 | 194,045.00 | 4.86B | 23,084,267 | — | ↗ |
| 2016-03-16 | FRY JOHN A | Director | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-03-07 | SAVAS PAUL G | Director | C-Conversion | A | Class A common stock | 6,522 | 0.00 | — | 36,522 | — | ↗ |
| 2016-03-03 | SAVAS PAUL G | Director | P-Purchase | A | Class A common stock | 5,000 | 5.74 | 28.7K | 41,522 | — | ↗ |
| 2016-02-12 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 10,000 | 5.83 | 58.3K | 1,980,666 | — | ↗ |
| 2016-02-05 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 10,000 | 6.43 | 64.3K | 1,970,666 | — | ↗ |
| 2016-02-04 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 20,000 | 6.05 | 121.0K | 1,960,666 | — | ↗ |
| 2016-01-15 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 10,000 | 6.58 | 65.8K | 1,940,666 | — | ↗ |
| 2016-01-12 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 10,000 | 6.43 | 64.3K | 1,930,666 | — | ↗ |
| 2015-12-18 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 15,000 | 6.40 | 96.1K | 1,915,666 | — | ↗ |
| 2015-12-16 | ALTSTIEL LARRY DOUGLAS | Officer | A-Award | A | Employee stock option (right to buy) | 140,000 | 0.00 | — | 140,000 | — | ↗ |
| 2015-12-15 | Spiegel Noel Joseph | Director | P-Purchase | A | Class A common stock | 5,710 | 6.20 | 35.4K | 6,000 | — | ↗ |
| 2015-12-01 | ALTSTIEL LARRY DOUGLAS | Officer | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-11-19 | Spiegel Noel Joseph | Director | P-Purchase | A | Class A common stock | 290 | 6.20 | 1.8K | 290 | — | ↗ |
| 2015-10-05 | SAVAS PAUL G | Director | J-Other | A | Nonvoting Common Units and Class B common stock | 6,522 | — | — | 6,522 | — | ↗ |
| 2015-10-01 | PERELMAN RONALD O | 10% Owner | J-Other | A | Nonvoting Common Units and Class B common stock | 0 | 0.00 | — | 23,059,232 | — | ↗ |
| 2015-09-25 | SAVAS PAUL G | Director | P-Purchase | A | Class A common stock | 5,000 | 6.62 | 33.1K | 20,000 | — | ↗ |
| 2015-09-25 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 25,555 | 5.77 | 147.4K | 1,866,221 | — | ↗ |
| 2015-09-22 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 24,000 | 6.82 | 163.6K | 1,830,666 | — | ↗ |
| 2015-08-26 | PERELMAN RONALD O | 10% Owner | J-Other | D | Nonvoting Common Units and Class B common stock | 1,344,186 | 0.00 | — | 23,655,814 | — | ↗ |
| 2015-08-07 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 10,000 | 8.66 | 86.6K | 1,806,666 | — | ↗ |
| 2015-08-04 | Spiegel Noel Joseph | Director | A-Award | A | Director stock option (right to buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2015-08-04 | SAVAS PAUL G | Director | P-Purchase | A | Class A common stock | 15,000 | 15.00 | 225.0K | 15,000 | — | ↗ |
| 2015-08-04 | Parker Craig C | Director | A-Award | A | Director stock option (right to buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2015-08-04 | PERELMAN RONALD O | Director | P-Purchase | A | Class A common stock | 1,666,666 | 15.00 | 25.00M | 1,666,666 | — | ↗ |
| 2015-08-04 | KINDLER JEFFREY B | Officer | A-Award | A | Director stock option (right to buy) | 28,121 | 0.00 | — | 28,121 | — | ↗ |
| 2015-08-04 | Holcombe Stephen L. | Officer | A-Award | A | Employee stock option (right to buy) | 180,469 | 0.00 | — | 180,469 | — | ↗ |
| 2015-08-04 | HOWARD RUDY | Officer | P-Purchase | A | Class A common stock | 5,000 | 15.00 | 75.0K | 5,000 | — | ↗ |
| 2015-08-04 | Cohen Steven Michael | Director | P-Purchase | A | Class A common stock | 5,000 | 15.00 | 75.0K | 5,000 | — | ↗ |
| 2015-07-30 | Spiegel Noel Joseph | Director | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-07-30 | SAVAS PAUL G | Director | — | D | Class B Units | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-07-30 | Parker Craig C | Director | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-07-30 | PERELMAN RONALD O | Director | — | I | Nonvoting Common Units and Class B common stock | 25,000,000 | 0.00 | — | 0 | — | ↗ |
| 2015-07-30 | MEISTER PAUL M | Director | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-07-30 | KINDLER JEFFREY B | Officer | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-07-30 | Holcombe Stephen L. | Officer | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-07-30 | HOWARD RUDY | Officer | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-07-30 | Cohen Steven Michael | Director | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
2.62M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Paul Sekhri President and Chief Executive Officer | 673.0K | — | — | 5.60M | 343.2K | 20.3K | 6.64M | 84.39% | ↗ |
| 2 | 2025 | Michael Tung Executive Vice President and Chief Financial Officer | 279.5K | — | — | 2.02M | 135.0K | 8.7K | 2.44M | 82.67% | ↗ |
| 3 | 2025 | Steven Tuch Former Executive Vice President and Chief Financial Officer | 107.4K | — | — | — | — | 34.9K | 142.3K | 0.00% | ↗ |
| 4 | 2024 | Paul Sekhri President and Chief Executive Officer | 621.7K | — | — | 2.95M | 273.0K | 20.2K | 3.86M | 76.32% | ↗ |
| 5 | 2024 | Steven Tuch Executive Vice President and Chief Financial Officer | 450.0K | — | — | 928.6K | 126.0K | 15.7K | 1.52M | 61.08% | ↗ |
| 6 | 2024 | Steven Tuch Former Executive Vice President and Chief Financial Officer | 450.0K | — | — | 928.6K | 126.0K | 15.7K | 1.52M | 61.08% | ↗ |
| 7 | 2023 | Paul Sekhri President and Chief Executive Officer | 480.0K | — | — | — | 831.0K | 20.9K | 1.33M | 0.00% | ↗ |
| 8 | 2023 | Steven Tuch Executive Vice President and Chief Financial Officer | 450.0K | — | — | — | 205.0K | 15.2K | 670.2K | 0.00% | ↗ |
| 9 | 2022 | Paul Sekhri President and Chief Executive Officer | 200.0K | — | — | 1.52M | — | 3.4K | 1.72M | 88.18% | ↗ |
| 10 | 2022 | Deepa Prasad Former President and Chief Executive Officer | 158.0K | — | — | — | 325.0K | 844.0K | 1.33M | 0.00% | ↗ |
| 11 | 2022 | Richard Nelson Executive Vice President of Corporate Development | 166.7K | — | — | 346.3K | — | 1.1K | 514.1K | 67.37% | ↗ |
| 12 | 2022 | Steven Tuch Executive Vice President and Chief Financial Officer | 29.0K | — | — | 350.9K | — | — | 379.9K | 92.37% | ↗ |
| 13 | 2022 | Barry Brown Chief Accounting Officer | 210.9K | — | — | 122.8K | 26.3K | 7.5K | 367.5K | 33.41% | ↗ |
| 14 | 2021 | Deepa Prasad Former President and Chief Executive Officer | 132.7K | — | — | 3.16M | — | — | 3.29M | 95.97% | ↗ |
| 15 | 2021 | Stephen L. Holcombe Former President and Chief Executive Officer | 359.8K | — | — | 780.5K | — | 771.0K | 1.91M | 40.84% | ↗ |
| 16 | 2021 | Rudy C. Howard Former Executive Vice President, Chief Financial Officer | 299.1K | — | — | 179.9K | — | 402.4K | 881.5K | 20.41% | ↗ |
| 17 | 2020 | Stephen L. Holcombe Former President and Chief Executive Officer | 450.0K | — | — | 716.4K | 225.0K | 9.8K | 1.40M | 51.13% | ↗ |
| 18 | 2020 | Stephen L. Holcombe President and Chief Executive Officer | 450.0K | — | — | 716.4K | 225.0K | 9.7K | 1.40M | 51.13% | ↗ |
| 19 | 2020 | Rudy C. Howard Former Executive Vice President, Chief Financial Officer | 325.0K | — | — | 447.7K | 130.0K | 32.2K | 934.9K | 47.89% | ↗ |
| 20 | 2020 | Rudy C. Howard Executive Vice President, Chief Financial Officer | 325.0K | — | — | 447.7K | 130.0K | 32.2K | 934.9K | 47.89% | ↗ |
| 21 | 2020 | Robin E. Abrams Chairperson of the Board of Directors | 300.0K | — | — | 179.1K | 120.0K | — | 599.1K | 29.89% | ↗ |
| 22 | 2020 | Robin E. Abrams Former Chairperson of the Board of Directors | 300.0K | — | — | 179.1K | 120.0K | — | 599.1K | 29.89% | ↗ |
| 23 | 2019 | Stephen L. Holcombe President and Chief Executive Officer | 450.0K | — | — | 373.0K | — | 9.8K | 832.8K | 44.79% | ↗ |
| 24 | 2019 | Rudy C. Howard Executive Vice President, Chief Financial Officer | 325.0K | — | — | 233.1K | — | 33.3K | 591.4K | 39.42% | ↗ |
| 25 | 2019 | Robin E. Abrams Chairperson of the Board of Directors | 300.0K | — | — | 93.2K | — | 379.00 | 393.6K | 23.69% | ↗ |
| 26 | 2019 | Jeffrey B. Kindler Chairman of the Board of Directors | 235.0K | — | — | 42.0K | — | — | 277.0K | 15.18% | ↗ |
| 27 | 2018 | Stephen L. Holcombe President and Chief Executive Officer | 450.0K | — | — | — | — | 9.4K | 459.4K | 0.00% | ↗ |
| 28 | 2018 | Dr. Larry D. Altstiel Former Executive Vice President, Chief Medical Officer | 400.0K | — | — | — | — | 13.4K | 413.4K | 0.00% | ↗ |
| 29 | 2018 | Rudy C. Howard Executive Vice President, Chief Financial Officer | 325.0K | — | — | — | — | 32.2K | 357.2K | 0.00% | ↗ |
| 30 | 2018 | Jeffrey B. Kindler Chairman of the Board of Directors | 250.0K | — | — | — | — | — | 250.0K | 0.00% | ↗ |
| 31 | 2018 | Jeffrey B. Kindler Executive Chairman of the Company and our Board of Directors | 250.0K | — | — | — | — | — | 250.0K | 0.00% | ↗ |
| 32 | 2017 | Stephen L. Holcombe President and Chief Executive Officer | 450.0K | — | — | 691.5K | 95.6K | 8.7K | 1.25M | 55.51% | ↗ |
| 33 | 2017 | Dr. Larry D. Altstiel Executive Vice President, Chief Medical Officer | 400.0K | — | — | 536.4K | 34.0K | 22.4K | 992.8K | 54.03% | ↗ |
| 34 | 2017 | Dr. Larry D. Altstiel Former Executive Vice President, Chief Medical Officer | 400.0K | — | — | 536.4K | 34.0K | 22.4K | 992.8K | 54.03% | ↗ |
| 35 | 2017 | Rudy C. Howard Executive Vice President, Chief Financial Officer | 325.0K | — | — | 440.1K | 55.3K | 31.5K | 851.8K | 51.66% | ↗ |
| 36 | 2017 | Jeffrey B. Kindler Executive Chairman of the Company and our Board of Directors | 250.0K | — | 203.4K | — | — | — | 453.4K | 44.85% | ↗ |
| 37 | 2016 | Stephen L. Holcombe President and Chief Executive Officer | 450.0K | — | — | — | 225.0K | 7.1K | 682.1K | 0.00% | ↗ |
| 38 | 2016 | Dr. Larry D. Altstiel Executive Vice President, Chief Medical Officer | 400.0K | — | — | — | 160.0K | 22.2K | 582.2K | 0.00% | ↗ |
| 39 | 2016 | Rudy C. Howard Executive Vice President, Chief Financial Officer | 325.0K | — | — | — | 130.0K | 29.6K | 484.6K | 0.00% | ↗ |
| 40 | 2015 | Stephen L. Holcombe President and Chief Executive Officer | 450.5K | — | — | 1.93M | 225.0K | 9.9K | 2.61M | 73.76% | ↗ |
| 41 | 2015 | Rudy C. Howard Executive Vice President, Chief Financial Officer | 177.5K | — | — | 1.23M | 70.9K | 16.7K | 1.49M | 82.22% | ↗ |
| 42 | 2015 | Jeffrey B. Kindler Executive Chairman of the Company and our Board of Directors | 114.6K | — | — | 300.3K | — | — | 414.8K | 72.38% | ↗ |
| 43 | 2014 | Stephen L. Holcombe President and Chief Executive Officer | 278.8K | — | — | — | — | 7.8K | 286.6K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Paul J. Sekhri | Chief Executive Officer, President & Chairman of the Board | 1M | male |
| Michael Steven Tung | Executive Vice President & Chief Financial Officer | 595.7K | — |
| Barry Brown | Chief Accounting Officer | 312.0K | male |
| Richard S. Nelson | Executive Vice President of Corporate Development & Director | 201.1K | male |
| Martin Lafontaine | Chief Commercial Officer | — | male |
| Elizabeth Keiley | Executive Vice President & General Counsel | — | female |
| Carmen Valcarce | Chief Scientific Officer & Executive Vice President | — | — |
| Thomas Strack | Chief Medical Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VTVT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
